As of Wednesday close, ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) stock was up $0.53, moving up 1.85 percent to $29.25. The average number of shares traded per day over the past five days has been 1,412,780 shares. 5 times new highs have been achieved over the past 5 days, with a $2.66 gain in that time frame. In the last twenty days, the average volume was 1,774,390, while in the previous 50 days, it was 1,707,028.
Since last month, ACAD stock retreated -11.34%. Shares of the company fell to $26.10 on 08/09/23, the lowest level in the past month. A 52-week high of $33.99 was reached on 07/18/23 after having rallying from a 52-week low of $13.73. Since the beginning of this year, ACAD’s stock price has risen by 83.73% or $13.33, and marked a new high 27 times. However, the stock has declined by -13.95% since its 52-week high.
ACAD stock investors should be aware that ACADIA Pharmaceuticals Inc. (ACAD) stock had its last reported insider trading activity 34 days ago on Jul 14. DAVIS STEPHEN, the CEO of the company, disposed of 100,000 shares for $30.04 on Jul 14. It resulted in a $3,004,350 divestment by the insider. DAVIS STEPHEN sold 55,104 shares at an average price of $25.05 on Jul 12. The insider now owns 36,695 shares following the transaction. On Jul 11, CEO DAVIS STEPHEN sold 16,498 shares at $25.00 apiece. The transaction was valued at $412,450.
Valuation Metrics
The stock’s beta is 0.56. Besides these, the trailing price-to-sales (P/S) ratio of 8.46, the price-to-book (PB) ratio of 12.09.
Financial Health
In the three months ended June 29, ACADIA Pharmaceuticals Inc.’s quick ratio stood at 2.60, while its current ratio was 2.60, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 97.50% percent. In the year ended June 29, EBITDA margin amounted to -42.84%, whereas operating margins totaled -23.10%. Based on annual data, ACAD earned $507.07 million in gross profit and brought in $517.24 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -56.50%. Return on equity (ROE) for the past 12 months was -27.80%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ACAD’s revenue rose 18.57% to $118.46 million during the quarter, while net income inched up to $165.24 million. While analysts expected ACADIA Pharmaceuticals Inc. to report -$0.08 quarterly earnings, the actual figure was $0.01 per share, beating the consensus estimate by 112.50%. During the quarter, the company generated $3.31 million in EBITDA. The liabilities of ACADIA Pharmaceuticals Inc. were 246.98 million at the end of its most recent quarter ended June 29, and its total debt was $58.84 million. The value of shareholders’ equity is $163.73 million.
Technical Picture
This quick technical analysis looks at ACADIA Pharmaceuticals Inc.’s (ACAD) price momentum. With a historical volatility rate of 21.88%, the RSI 9-day stood at 64.55% on 16 August.
With respect to its five-day moving average, the current ACADIA Pharmaceuticals Inc. price is up by +10.00% percent or $2.66. At present, ACAD shares trade -8.34% below its 20-day simple moving average and +59.66% percent above its 100-day simple moving average. However, the stock is currently trading approximately +22.03% above its SMA50 and +86.31% above its SMA200.
Stochastic coefficient K was 68.43% and Stochastic coefficient D was 50.47%, while ATR was 1.04. Given the Stochastic reading of 80.95% for the 14-day period, the RSI (14) reading has been calculated as 60.42%. As of today, the MACD Oscillator reading stands at 1.18, while the 14-day reading stands at 0.74.
Analyst Ratings
Guggenheim upgraded its rating on ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) to a Buy in a note to investors on January 03, 2023. The analysts firm previously had a Neutral rating on the stock.ACADIA Pharmaceuticals Inc. (ACAD) has been rated Overweight by analysts. According to 1 brokerage firm, ACAD is a sell, and 8 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate ACADIA Pharmaceuticals Inc. stock as buy, with 8 recommending it as overweight.
With a median target price of $33.00, the current consensus forecast for the stock is $13.00 – $42.00. Based on these forecasts, analysts predict ACADIA Pharmaceuticals Inc. (ACAD) will achieve an average price target of $31.13.
